Hospital

At 28 to 179 days, COVID-19 infection in patients with preexisting chronic kidney disease (CKD) was associated with an increased risk of composite kidney events.

Iman Ahmed, PharmD, BCOP, shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

Pharmacy technicians have a pivotal opportunity to advance professionally by proactively demonstrating leadership, offering solutions, and clearly communicating their value to health care leaders.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, shared insight from the HOPA Annual Meeting 2025.

The safety profile of diazepam nasal spray among pediatric patients was consistent with older patients, supporting its use in this age group.

Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

The designation was supported based on data from the randomized, double-blind, active-controlled phase 3 interchangeability study.

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

SOC emphasizes adaptability and individual professional judgment without compromising quality, as individuals are held to the standard and expertise of their practice area.

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Expert provides a comprehensive overview of drug diversion prevention in pharmacy settings.

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Christine Barrett, PharmD, BCOP, shares insights, challenges, and advice for oncology pharmacists navigating neoadjuvant therapy.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

These data provide compelling evidence to revise existing transfusion protocols, recommending 4F-PCC as the preferred treatment for hemostatic management in cardiac surgery.

This approval marks bevacizumab-nwgd as the sixth reference product to bevacizumab (Avastin).

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Automated diagnosis verification offers a promising alternative for managing the use of GLP-1 medications.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.